.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Recent Advances in MDS and CML

EP. 1: Introduction: Treatment Landscape of MDS

January 9th 2014

EP. 2: Discontinuation of Treatment With TKIs in CML

January 9th 2014

EP. 3: Frontline Treatment of Chronic Myelogenous Leukemia

January 9th 2014

EP. 4: Second-Generation Tyrosine Kinase Inhibitors in CML

January 9th 2014

EP. 5: Treatment Selection for Resistant or Intolerant CML

January 9th 2014

EP. 6: Hypomethylating Agents in the Treatment of High-Risk MDS

January 9th 2014

EP. 7: Role of Genetic Testing in Myelodysplastic Syndromes

January 9th 2014

EP. 8: Defining and Predicting Response to HMAs in MDS

January 9th 2014

EP. 9: Treatment of MDS Refractory to Hypomethylating Agent

January 9th 2014

EP. 10: Current and Future Treatment Landscape for MDS

January 9th 2014

EP. 11: Novel Agents and Treatment Strategies in MDS

January 9th 2014

EP. 12: Oral Azacitidine and Lenalidomide Combinations in MDS

January 9th 2014

EP. 13: Final Thoughts on Clinical Advances in MDS and CML

January 9th 2014